Newton Robert, Ziegler John, Bourboulia Dimitra, Casabonne Delphine, Beral Valerie, Mbidde Edward, Carpenter Lucy, Reeves Gillian, Parkin D Maxwell, Wabinga Henry, Mbulaiteye Sam, Jaffe Harold, Weiss Robin, Boshoff Chris
Cancer Research UK, Epidemiology Unit, Radcliffe Infirmary, Oxford, United Kingdom.
Int J Cancer. 2003 Jan 10;103(2):226-32. doi: 10.1002/ijc.10817.
The association between the prevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV or human herpesvirus 8 [HHV-8]) and sociodemographic, sexual, reproductive and lifestyle factors was investigated in a study of adults presenting with cancer at hospitals in Kampala, Uganda. Patients were interviewed and tested for antibodies against KSHV (using an indirect immunofluorescent assay). Data are presented for 607 patients who were not infected with the human immunodeficiency virus-1 (HIV) and who did not have Kaposi's sarcoma (these included people with cancers of the uterine cervix [140], breast [58], liver [41], oesophagus [36], lymphoma [47], other cancers [285] and benign tumours [63]). The prevalence of anti-KSHV antibodies was 50% overall (302/607) and did not differ significantly by cancer site (p = 0.4) or sex (p = 0.2), but increased linearly with age from 35% in those under 25 years to 55% in those 45 years and over (chi(2) trend [1 df] = 9.1; p < 0.001). After adjusting for age and sex, anti-KSHV antibodies were more common in tribal groups other than the Baganda tribe (54% vs. 45% among Baganda; p = 0.02), but there was no significant (p > 0.05) variation in seroprevalence by district of birth, region of residence prior to becoming ill or various measures of wealth. The prevalence of anti-KSHV antibodies decreased with increasing number of older siblings, although this may be due to chance (p = 0.05) and was higher among people who had ever been married (p = 0.03). There was no significant association (p > 0.05) between the presence of antibodies against KSHV and other sexual and reproductive factors. Among the 302 patients with anti-KSHV antibodies, the proportion with high titres increased linearly with increasing age (p = 0.03) and was higher among those reporting having had a blood transfusion (p = 0.03). In conclusion, in this population in Uganda, where KSHV is relatively common, the prevalence of anti-KSHV antibodies increased with age but showed little association with nearly 50 other factors studied.
在乌干达坎帕拉的医院对成年癌症患者进行的一项研究中,调查了卡波西肉瘤相关疱疹病毒(KSHV或人类疱疹病毒8型[HHV - 8])抗体流行率与社会人口统计学、性、生殖和生活方式因素之间的关联。对患者进行访谈并检测KSHV抗体(采用间接免疫荧光测定法)。呈现了607例未感染人类免疫缺陷病毒1型(HIV)且未患卡波西肉瘤患者的数据(这些患者包括子宫颈癌患者[140例]、乳腺癌患者[58例]、肝癌患者[41例]、食管癌患者[36例]、淋巴瘤患者[47例]、其他癌症患者[285例]和良性肿瘤患者[63例])。抗KSHV抗体的总体流行率为50%(302/607),在癌症部位(p = 0.4)或性别方面无显著差异(p = 0.2),但随年龄呈线性增加,从2岁以下人群中的35%增至45岁及以上人群中的55%(卡方趋势[1自由度]= 9.1;p < 0.001)。在对年龄和性别进行调整后,除巴干达部落外的其他部落群体中抗KSHV抗体更为常见(巴干达部落中为45%,其他部落为54%;p = 0.02),但按出生地、患病前居住地区或各种财富衡量指标,血清阳性率无显著差异(p > 0.05)。抗KSHV抗体的流行率随年长同胞数量增加而降低,不过这可能是偶然因素所致(p = 0.05),且在已婚者中更高(p = 0.03)。抗KSHV抗体的存在与其他性和生殖因素之间无显著关联(p > 0.05)。在302例有抗KSHV抗体的患者中,高滴度抗体的比例随年龄增加呈线性增加(p = 0.03),且在报告接受过输血的患者中更高(p = 0.03)。总之,在乌干达这个KSHV相对常见的人群中,抗KSHV抗体的流行率随年龄增加,但与所研究的近50个其他因素几乎无关联。